Destiny Pharma PLC (LON:DEST) said Bill Love, its chief scientific officer, has joined the UK Research and Innovation (UKRI) COVID-19 Research and Innovation Taskforce.
He will advise on the ‘delivery’ of research and innovation funding.
Love said: "I am honoured to join the UKRI Taskforce, created to focus on the strength and creativity of the UK's world-class research base.
“I look forward to supporting UKRI in the identification of research and innovation projects to tackle this significant challenge worldwide."
Destiny, a clinical-stage biotechnology company, is currently jointly developing SPOR-COV, for the prevention of COVID-19 and other viral respiratory infections.